GlassScriptPhysician profile
Ashwin K Gupta
NPI 1033766480
$32,819.30
in general payments reported to CMS, 2019-2025
16 companies · $28K in 2025
The $28K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,449 · 2022: $1,155 · 2023: $1,536 · 2024: $272 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Travel and Lodging: $6,961 · Consulting Fee: $4,980 · Food and Beverage: $3,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,007.50 |
| Travel and Lodging | $6,961.04 |
| Consulting Fee | $4,980.00 |
| Food and Beverage | $3,266.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $28,798.47 | 2022-2025 | Yeztugo, Descovy, Biktarvy |
| Abbvie INC. | $974.57 | 2022-2024 | |
| Novo Nordisk INC | $789.66 | 2021-2022 | |
| Viiv Healthcare Company | $489.67 | 2021-2025 | Rukobia |
| Glaxosmithkline, LLC. | $466.00 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $253.50 | 2023 | Ultomiris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.39 | 2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $121.82 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $121.56 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $118.48 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.43 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.51 | 2025 | |
| Merck Sharp & Dohme LLC | $92.16 | 2023 | Zerbaxa |
| Sk Life Science, INC. | $85.30 | 2022 | |
| Janssen Products, LP | $73.57 | 2023 | Symtuza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $28.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwin Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.